Imagen de Portada

Bevacizumab for metastatic colorectal cancer with chromosomal instability: cost-effectiveness analysis for a novel precision treatment approach in Germany, Ireland and Spain

Bevacizumab was approved for first-line treatment of metastatic colorectal cancer (mCRC) in 2004. However, adding bevacizumab to treatment consistently fails to be cost-effective owing to modest response rates. Recently, the European Commission (EC) funded ANGIOPREDICT consortium (www.angiopredict.c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Briody, Jonathan (Autor) , Miller, Ian S. (Autor) , O'Mahony, James F. (Autor) , Tilson, Lesley (Autor) , O’Farrell, Alice C. (Autor) , Chen, Qiushi (Autor) , Murphy, Verena (Autor) , Casey, Orla (Autor) , Schulte, Nadine (Autor) , Ebert, Matthias (Autor) , Prehn, Jochen H. M. (Autor) , Lambrechts, Diether (Autor) , Ylstra, Bauke (Autor) , Dienstmann, Rodrigo (Autor) , Byrne, Annette T. (Autor) , Bennett, Kathleen (Autor)
Formato: Article (Journal)
Lenguaje:inglés
Publicado: March 2026
In: PharmacoEconomics
Year: 2026, Volumen: 44, Número: 3, Pages: 359-374
ISSN:1179-2027
DOI:10.1007/s40273-025-01585-x
Acceso en línea:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s40273-025-01585-x
Enlace del recurso
Notas de Autor:Jonathan Briody, Ian S. Miller, James F. O’Mahony, Lesley Tilson, Alice C. O’Farrell, Qiushi Chen, Verena Murphy, Orla Casey, Nadine Schulte, Matthias P. Ebert, Jochen H.M. Prehn, Diether Lambrechts, Bauke Ylstra, Rodrigo Dienstmann, Annette T. Byrne, Kathleen Bennett
Descripción
Sumario:Bevacizumab was approved for first-line treatment of metastatic colorectal cancer (mCRC) in 2004. However, adding bevacizumab to treatment consistently fails to be cost-effective owing to modest response rates. Recently, the European Commission (EC) funded ANGIOPREDICT consortium (www.angiopredict.com) identified a link between bevacizumab treatment response and intermediate-to-high chromosomal instability (CIN) in mCRC. Thus, the objective of the current study was to compare the cost-effectiveness of adding bevacizumab with first-line chemotherapy in the bevacizumab responsive CIN subtype across three European countries (Germany, Ireland and Spain) with varying costs of care and reimbursement policies.
Notas:Online veröffentlicht: 4. Februar 2026
Gesehen am 10.03.2026
Descripción Física:Online Resource
ISSN:1179-2027
DOI:10.1007/s40273-025-01585-x

Ejemplares similares